Feature Channels:

In diseases like cancer, atherosclerosis, and sickle cell anemia, cathepsins promote their propagation. Drug trials to inhibit these enzymes have failed due to baffling side effects. Now a new study examines cathepsins in systems to remove some of the bafflement.

Channels: All Journal News, Grant Funded News, Blood, Cancer, Clinical Trials, Pharmaceuticals, Embargoed Feed - hidden,

Keywords: Cathepsin, cathepsins, Protease, Protease Inhibitor, Protease Inhibitor Drugs, Systems Biology, Cancer, Sickle Cell Anemia, Sickle Cell Anemia Research, Sickle Cell Disease, Breast Cancer, Breast Cancer Metastasis, atheroscleroisis, Cannibalization, Distracting, autodigestion, cathepsin K, cathepsin L, cathepsin S

A variety of existing drugs for treating conditions such as diabetes, inflammation, alcohol abuse, and arthritis in dogs can also kill cancer cells in the lab, according to a study by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.

Channels: All Journal News, Grant Funded News, Cancer, Clinical Trials, Pharmaceuticals, National Institutes of Health (NIH), Nature (journal), Cancer Center Featured Story 2, Embargoed Feed - hidden,

Keywords: Dana-Farber Cancer Institute, Dana-Farber, Broad Institute of MIT and Harvard, drug repurposing

Mice given a new drug targeting a key gene involved in lipid and glucose metabolism could tolerate a high-fat diet regimen (composed of 60% fat from lard) without developing significant liver damage, becoming obese, or disrupting their body’s glucose balance.

Channels: Clinical Trials, Liver Disease, Obesity, Pharmaceuticals, Weight Loss, National Institutes of Health (NIH), Grant Funded News,

Keywords: Nash, Liver Cancer

Acid reflux drugs that are sometimes recommended to ease stomach problems during cancer treatment may have an unintended side effect: impairment of breast cancer survivors’ memory and concentration.

Channels: Cancer, Clinical Trials, Cognition and Learning, Digestive Disorders, Neuro, Pharmaceuticals, Women's Health, All Journal News, Staff Picks,

Keywords: Breast Cancer Survival, acid reflux drugs, Proton Pump Inhibitors, Memory & Cognitive Processes, Concentration, Side Effects

The Jan. 17 issue of the Journal of the American Medical Association (JAMA) features an important study about sepsis with an accompanying editorial by a University of Nebraska Medical Center expert. The study and editorial sets the record straight on an unproven therapy some physicians use to treat sepsis, a deadly infectious disease. The editorial, written by Andre Kalil, M.D., M.P.H., professor of infectious diseases in the UNMC Department of Internal Medicine, writes in support of the new and rigorous international study based on a randomized clinical trial in Australia, published in the same issue. The editorial appears in the Jan. 17 online issue and also will appear in the Feb. 4 print edition.

Channels: Clinical Trials, Healthcare, Infectious Diseases, Pharmaceuticals, JAMA, Embargoed Feed - hidden, All Journal News, Blood,

Keywords: Sepsis

When University of California, Irvine neurobiologist Carey Y.L. Huh, Ph.D., set her sights on discovering more about amblyopia, she brought personal insight to her quest. As a child, Huh was diagnosed with the condition, which is often called “lazy eye.” he and her colleagues have just found that amblyopia originates in an earlier stage of the visual pathway than was previously thought. Their research, which raises the possibility of new treatment approaches, appears in the Journal of Neuroscience.

Channels: Pharmaceuticals, Vision, National Institutes of Health (NIH), Children's Health, Healthcare, All Journal News, Staff Picks,

Keywords: Neurobiology, Vision, lazy eye treatment

A study of more than 4 million Medicaid claims records during a recent seven-year period concludes that less than a third of the nearly 3,800 U.S. adolescents and young adults who experienced a nonfatal opioid overdose got timely (within 30 days) follow-up addiction treatment to curb or prevent future misuse and reduce the risk of a second overdose.

Channels: Addiction, All Journal News, Drugs and Drug Abuse, Pharmaceuticals, Children's Health, Children's Health Featured Story TOP, JAMA,

Keywords: Opioid Use Disorder, Overdose, Youths, addiction treatment

A team of physicists from McMaster University has developed a process to modify red blood cells so they can be used to distribute drugs throughout the body, which could specifically target infections or treat catastrophic diseases such as cancer or Alzheimer’s.

Channels: All Journal News, Alzheimer's and Dementia, Blood, Cancer, Cell Biology, Pharmaceuticals,

Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that cells from children with NGLY1 deficiency—a rare disorder first described in 2012—lack sufficient water channel proteins called aquaporins. The discovery was published in Cell Reports and may help explain the disorder’s wide-ranging symptoms—including the inability to produce tears, seizures and developmental delays—and opens new avenues to find therapies to treat the disorder.

Channels: Children's Health, Genetics, Healthcare, Pharmaceuticals, Staff Picks, Cell (journal), Embargoed Feed - hidden, All Journal News,

Keywords: rare disease, bertrand might, ngly1, NGLY1 deficiency, cdg

A young boy with a rare genetic disease that typically kills within weeks of birth is now 3 years old and in remission thanks to a collaborative effort that included physicians at King Saud University Department of Pediatrics and immunologists at the Icahn School of Medicine at Mount Sinai.

Channels: Genetics, Healthcare, Immunology, Pharmaceuticals, NEJM, Embargoed Feed - hidden, All Journal News,

Keywords: Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, Rare Genetic Disease, King Saud University, Pediatrics, The New England Journal Of Medicine, Genetics, Immunology, USP18 Gene, Collaboration, Microbiology, Clinical Care, Medicine, Science, Health Care, Study, Report, Patients, Inflammatory Disease, Children, Paris Descartes University, Gene V